quarterly, page-11

Looks to me like a few lemmings read the quarterly, saw no distribution deal signed and sold

These deals never run to expected timelines

The stock was previously 2c before any US, SE Asia, Brazil etc - it was valued at this simply on having a fantastic FDA approved product and huge market

Time to start pricing in some upside people as management have eluded to. Punters really should take notice of their subtle hints.

Remember they gave a few as to Brazil progress last year and then that lead to LOI followed by draft distribution deal which has now been expanded.

They mentioned a few lines repeatedly in reports regarding US, we now hear that a major has requested and tested product with favorable results.

Same story for SE Asia, we hear market has commenced to meetings with distributors scheduled for next month.

So while they are conservative, if they are saying that they think "material transactions" aren't reflected in the shareprice, they are conveying a pretty clear message

Been a long wait, but anyone not happy with the quarterly should read it again :)